Bank of New York Mellon’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-58,553
| Closed | -$12.9M | – | 4218 |
|
|
2025
Q4 | $12.9M | Buy |
58,553
+12,718
| +28% | +$2.06M | ﹤0.01% | 1776 |
|
|
2025
Q3 | $4.39M | Sell |
45,835
-4,063
| -8% | -$259K | ﹤0.01% | 2394 |
|
|
2025
Q2 | $2.43M | Buy |
+49,898
| New | +$1.2M | ﹤0.01% | 2650 |
|
|
2024
Q1 | – | Sell |
-6,327
| Closed | -$100K | – | 4182 |
|
|
2023
Q4 | $100K | Buy |
6,327
+2,300
| +57% | +$36.9K | ﹤0.01% | 4082 |
|
|
2023
Q3 | $75.9K | Sell |
4,027
-36
| -0.9% | -$707 | ﹤0.01% | 4121 |
|
|
2023
Q2 | $91.8K | Buy |
4,063
+352
| +9% | +$8.27K | ﹤0.01% | 4096 |
|
|
2023
Q1 | $94.2K | Buy |
+3,711
| New | +$105K | ﹤0.01% | 4085 |
|
|
2021
Q2 | – | Sell |
-4,014
| Closed | -$214K | – | 4401 |
|
|
2021
Q1 | $214K | Buy |
4,014
+74
| +2% | +$3.65K | ﹤0.01% | 4029 |
|
|
2020
Q4 | $158K | Sell |
3,940
-203
| -5% | -$10.1K | ﹤0.01% | 4022 |
|
|
2020
Q3 | $236K | Sell |
4,143
-29
| -0.7% | -$2.05K | ﹤0.01% | 3791 |
|
|
2020
Q2 | $308K | Buy |
+4,172
| New | +$270K | ﹤0.01% | 3685 |
|
|
2019
Q2 | – | Sell |
-996
| Closed | -$53K | – | 4220 |
|
|
2019
Q1 | $53K | Buy |
+996
| New | +$54.6K | ﹤0.01% | 4085 |
|
|
2017
Q2 | – | Sell |
-2,118
| Closed | -$330K | – | 4303 |
|
|
2017
Q1 | $330K | Buy |
2,118
+133
| +7% | +$23.4K | ﹤0.01% | 3721 |
|
|
2016
Q4 | $413K | Buy |
1,985
+676
| +52% | +$140K | ﹤0.01% | 3669 |
|
|
2016
Q3 | $300K | Sell |
1,309
-45
| -3% | -$10.4K | ﹤0.01% | 3760 |
|
|
2016
Q2 | $279K | Buy |
1,354
+533
| +65% | +$129K | ﹤0.01% | 3768 |
|
|
2016
Q1 | $208K | Buy |
821
+4
| +0.5% | +$922 | ﹤0.01% | 3774 |
|
|
2015
Q4 | $280K | Buy |
817
+91
| +13% | +$27.3K | ﹤0.01% | 3757 |
|
|
2015
Q3 | $184K | Buy |
726
+116
| +19% | +$33.2K | ﹤0.01% | 3933 |
|
|
2015
Q2 | $171K | Buy |
+610
| New | +$188K | ﹤0.01% | 3924 |
|
Bank of New York Mellon's CDTX Position: Q1 2026 in Review
Bank of New York Mellon sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 58,553 shares — an estimated $12.9M sold.
Bank of New York Mellon first reported a position in CDTX in Q2 2015 and held it in 20 quarters. The position peaked at $12.9M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Bank of New York Mellon reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Bank of New York Mellon sold 58,553 Cidara Therapeutics shares in Q1 2026, an estimated $12.9M.
- Bank of New York Mellon first reported a position in Cidara Therapeutics in Q2 2015 and held it in 20 quarters.
- Bank of New York Mellon's Cidara Therapeutics position peaked at $12.9M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Bank of New York Mellon's 13F filing for Q1 2026, filed 5 May 2026.